Evidence map›Paper›PMID 31694907›Full record

ReviewCancer research2020

Epigenetic Aging: More Than Just a Clock When It Comes to Cancer.

Ming Yu, William D Hazelton, Georg E Luebeck, William M Grady

Registry-linked trialAbstract readReview
In one paragraph

Review in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The Bidirectional Relationship Between Diabetes and Cancer: Mechanistic Insights, Epigenetic Intermediaries, and Therapeutic Approaches.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Intermittent fasting enhances cancer therapyWorld journal of clinical oncology · 2026
    Review
  10. Review
  11. Association of Epigenetic Aging Biomarkers With Risk of MASLD-Related HCC.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ming Yu *Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. myu@fredhutch.org wgrady@fredhutch.org.
William D HazeltonProgram in Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-7975-5080
Georg E LuebeckProgram in Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-4378-2829
William M Grady *Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. myu@fredhutch.org wgrady@fredhutch.org.ORCID 0000-0002-0129-7809

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Tumor mutation signaturesP01CA077852 · NCI · UNIVERSITY OF WASHINGTON · PI SIDOROVA, JULIA · 1999 to 2019
$26.0M
Trans-NetworkU54CA143862 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI DAVIES, PAUL · 2009 to 2013
$8.4M
The Colon Cancer Family Registry: SeattleU24CA074794 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWCOMB, POLLY A · 2008 to 2011
$7.0M
Identify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7M
Controlling Esophageal Cancer: A Collaborative Modeling ApproachU01CA199336 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2015 to 2019
$5.9M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
NSAID and COX/PG Metabolism and Colorectal CancerR01CA112516 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ULRICH, CORNELIA M · 2005 to 2009
$3.6M
Esophageal Cancer from Cells to Population: A Multiscale ApproachU01CA182940 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2013 to 2017
$3.3M
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.R01CA220004 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, HALBERG, RICHARD BROTT · 2017 to 2021
$3.2M
A Prospective Study of Colorectal Cancer: One-Carbon Metabolism and InflammationR01CA120523 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ULRICH, CORNELIA M · 2008 to 2012
$3.0M
Prostaglandin Synthesis, Genetics and Colorectal CancerR01CA114467 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ULRICH, CORNELIA M · 2006 to 2010
$2.7M
NCI NIH HHS P01 CA077852NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA112516NCI NIH HHS R01 CA114467NCI NIH HHS R01 CA120523NCI NIH HHS R01 CA194663NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA220004NCI NIH HHS R03 CA165153NCI NIH HHS R50 CA233042NCI NIH HHS U01 CA152756NCI NIH HHS U01 CA182940NCI NIH HHS U01 CA199336NCI NIH HHS U24 CA074794NCI NIH HHS U54 CA143862
6 · The paper itself

Abstract

The incidence of cancer, adjusted for secular trends, is directly related to age, and advanced chronologic age is one of the most significant risk factors for cancer. Organismal aging is associated with changes at the molecular, cellular, and tissue levels and is affected by both genetic and environmental factors. The specific mechanisms through which these age-associated molecular changes contribute to the increased risk of aging-related disease, such as cancer, are incompletely understood. DNA methylation, a prominent epigenetic mark, also changes over a lifetime as part of an "epigenetic aging" process. Here, we give an update and review of epigenetic aging, in particular, the phenomena of epigenetic drift and epigenetic clock, with regard to its implication in cancer etiology. We discuss the discovery of the DNA methylation-based biomarkers for biological tissue age and the construction of various epigenetic age estimators for human clinical outcomes and health/life span. Recent studies in various types of cancer point to the significance of epigenetic aging in tumorigenesis and its potential use for cancer risk prediction. Future studies are needed to assess the potential clinical impact of strategies focused on lowering cancer risk by preventing premature aging or promoting healthy aging.

Indexed as

AgingEpigenomicsAnimalsDNA MethylationHumansNeoplasms

Identifiers

PMID31694907
PMCPMC7002254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.